Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

744 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.
Igarashi T, Ogura M, Itoh K, Taniwaki M, Ando K, Kuroda Y, Yamamoto K, Uike N, Tomita A, Nagai H, Kurosawa M, Mori S, Nawano S, Terauchi T, Ohashi Y, Tobinai K. Igarashi T, et al. Among authors: kurosawa m. Int J Hematol. 2017 Jan;105(1):109-110. doi: 10.1007/s12185-016-2155-3. Int J Hematol. 2017. PMID: 27896571 No abstract available.
Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan.
Itoh K, Kinoshita T, Watanabe T, Yoshimura K, Okamoto R, Chou T, Ogura M, Hirano M, Asaoku H, Kurosawa M, Maeda Y, Omachi K, Moriuchi Y, Kasai M, Ohnishi K, Takayama N, Morishima Y, Tobinai K, Kaba H, Yamamoto S, Fukuda H, Kikuchi M, Yoshino T, Matsuno Y, Hotta T, Shimoyama M. Itoh K, et al. Among authors: kurosawa m. Int J Hematol. 2010 Apr;91(3):446-55. doi: 10.1007/s12185-010-0533-9. Epub 2010 Mar 3. Int J Hematol. 2010. PMID: 20198461
Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas.
Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, Yamaguchi M, Kurosawa M, Tsukasaki K, Kasai M, Tobinai K, Kaba H, Mukai K, Nakamura S, Ohshima K, Hotta T, Shimoyama M. Watanabe T, et al. Among authors: kurosawa m. Leuk Lymphoma. 2010 May;51(5):813-21. doi: 10.3109/10428191003721359. Leuk Lymphoma. 2010. PMID: 20367565
Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia.
Kikuchi M, Tanaka J, Kondo T, Hashino S, Kasai M, Kurosawa M, Iwasaki H, Morioka M, Kawamura T, Masauzi N, Fukuhara T, Kakinoki Y, Kobayashi H, Noto S, Asaka M, Imamura M. Kikuchi M, et al. Among authors: kurosawa m. Int J Hematol. 2010 Oct;92(3):481-9. doi: 10.1007/s12185-010-0670-1. Epub 2010 Sep 10. Int J Hematol. 2010. PMID: 20830615 Free article.
Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K, Igarashi T, Itoh K, Kurosawa M, Nagai H, Hiraoka A, Kinoshita T, Uike N, Ogura M, Nawano S, Mori S, Ohashi Y; IDEC-C2B8 Study Group. Tobinai K, et al. Among authors: kurosawa m. Cancer Sci. 2011 Sep;102(9):1698-705. doi: 10.1111/j.1349-7006.2011.02001.x. Epub 2011 Jul 8. Cancer Sci. 2011. PMID: 21645173 Free article. Clinical Trial.
Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402.
Azuma T, Tobinai K, Takeyama K, Shibata T, Hidaka M, Kurosawa M, Kasai M, Chou T, Fukushima N, Mukai K, Tsukasaki K, Shimoyama M; Japan Clinical Oncology Group-Lymphoma Study Group (JCOG-LSG), Tokyo, Japan. Azuma T, et al. Among authors: kurosawa m. Jpn J Clin Oncol. 2012 May;42(5):394-404. doi: 10.1093/jjco/hys029. Epub 2012 Mar 15. Jpn J Clin Oncol. 2012. PMID: 22422899 Clinical Trial.
A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group.
Torimoto Y, Sato K, Ikuta K, Hayashi T, Hirayama Y, Inamura J, Kobayashi H, Kobayashi R, Koda K, Kurosawa M, Mori A, Ota S, Sakai H, Shigematsu A, Shindo M, Shinzaki H, Takahashi F, Takimoto R, Tanaka J, Yamamoto S, Kohgo Y, Fukuhara T. Torimoto Y, et al. Among authors: kurosawa m. Int J Hematol. 2013 Aug;98(2):171-8. doi: 10.1007/s12185-013-1383-z. Epub 2013 Jun 29. Int J Hematol. 2013. PMID: 23813410 Clinical Trial.
Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A).
Fukushima T, Nomura S, Shimoyama M, Shibata T, Imaizumi Y, Moriuchi Y, Tomoyose T, Uozumi K, Kobayashi Y, Fukushima N, Utsunomiya A, Tara M, Nosaka K, Hidaka M, Uike N, Yoshida S, Tamura K, Ishitsuka K, Kurosawa M, Nakata M, Fukuda H, Hotta T, Tobinai K, Tsukasaki K. Fukushima T, et al. Among authors: kurosawa m. Br J Haematol. 2014 Sep;166(5):739-48. doi: 10.1111/bjh.12962. Epub 2014 Jun 14. Br J Haematol. 2014. PMID: 24931507 Free article.
Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group.
Hirayama Y, Ishitani K, Ota S, Kurosawa M, Kondo T, Takimoto R, Mori A, Sakai H, Torimoto Y, Yamamoto S, Sato K, Iwasaki H, Kohda K, Ishida T, Kakinoki Y, Fukuhara T, Kato J. Hirayama Y, et al. Among authors: kurosawa m. Int J Hematol. 2014 Sep;100(3):281-9. doi: 10.1007/s12185-014-1629-4. Epub 2014 Jul 23. Int J Hematol. 2014. PMID: 25052874
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F; LYM-3002 Investigators. Robak T, et al. N Engl J Med. 2015 Mar 5;372(10):944-53. doi: 10.1056/NEJMoa1412096. N Engl J Med. 2015. PMID: 25738670 Free article. Clinical Trial.
744 results